Health & Medical Cancer & Oncology

FDA: New Warning for Procrit, Epogen, Aranesp

FDA: New Warning for Procrit, Epogen, Aranesp

FDA: New Warning for Procrit, Epogen, Aranesp


Heart Attack, Stroke Risks Prompt Treatment Change for Chronic Kidney Disease Patients

June 24, 2011 -- New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease (CKD) may put them at risk of heart attack, stroke, and death, the FDA today warned.

More than 20 million Americans age 20 and older have CKD. All CKD patients taking these drugs should contact their doctors. Those taking the drugs for other conditions should be aware of the risk.

The drugs, all made by Amgen, are known as erythropoiesis-stimulating agents or ESAs. They signal the bone marrow to make more red blood cells and reduce anemia due to CKD or cancerchemotherapy.

Patients with CKD lose some of their ability to make new red blood cells and sometimes need blood transfusions. ESAs reduce the need for these transfusions.

Doctors test patients' hemoglobin levels to adjust ESA dosing. Currently, they have shot for a goal of 10 to 12 g/dL hemoglobin in patients with CKD.

But new evidence shows that patients who achieve this goal may have a significantly increased risk of heart attack, heart failure, stroke, and death.

Beginning immediately, the FDA says doctors and patients should abandon the concept of a target hemoglobin goal. Instead they should use only the smallest ESA dose needed to reduce transfusion frequency -- and should frequently test patients' blood to make sure hemoglobin levels don't get too high.

The advice is different for CKD patients on dialysis and for CKD patients not on dialysis.

For CKD patients on dialysis:
  • Begin ESA treatment when the hemoglobin level is less than 10 g/dL.
  • If the hemoglobin level approaches or reaches 11 g/dL, reduce the ESA dose or suspend treatment.

For CKD patients not on dialysis:
  • Consider ESA treatment only when the hemoglobin level is less than 10 g/dL, and the rate of hemoglobin level decline suggests need for a blood transfusion is likely, and a goal of treatment is to reduce the risk of immunization against non-self factors in transfused blood and/or reducing transfusion risks.
  • If the hemoglobin level goes over 10 g/dL, reduce the ESA dose or suspend treatment.

"We now recommend that doctors and patients should weigh the possible benefits of ESAs to decrease the need for red-blood-cell transfusion against increased risk of serious cardiovascular events," Robert C. Kane, MD, FDA acting deputy director for safety of hematology products, said at a news teleconference. "For each patient, doctors should individualize dosing and use only the dose sufficient to reduce the need for transfusions."
SHARE
RELATED POSTS on "Health & Medical"
Reasons Why There Is So Much Skin Cancer Now Days
Reasons Why There Is So Much Skin Cancer Now Days
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]-Special Population
Breast Cancer Screening (PDQ®): Screening - Health Professional Information [NCI]-Special Population
Mesothelioma – An Overview To A Deadly Cancer
Mesothelioma – An Overview To A Deadly Cancer
Is Massage A Natural Pain Relief?
Is Massage A Natural Pain Relief?
Could the HPV Test Replace the Pap Test?
Could the HPV Test Replace the Pap Test?
Diagnostic Tests - PET Scans
Diagnostic Tests - PET Scans
Elderly Receiving Neoadjuvant Chemoradiation for Rectal Cancer
Elderly Receiving Neoadjuvant Chemoradiation for Rectal Cancer
Routine Mammograms Found Not Helpful for Most Women Over 70
Routine Mammograms Found Not Helpful for Most Women Over 70
Meaty Diet Linked to Pancreatic Cancer
Meaty Diet Linked to Pancreatic Cancer
Advances in Transplantation Strategies for Multiple Myeloma
Advances in Transplantation Strategies for Multiple Myeloma
Bioavailability of Tyrosine Kinase Inhibitors
Bioavailability of Tyrosine Kinase Inhibitors
Tracking and Journaling the Cancer Journey
Tracking and Journaling the Cancer Journey
What You Need to Know About Benign Multicystic Mesothelioma
What You Need to Know About Benign Multicystic Mesothelioma
Essential Good Nutrition for Cancer Patients.
Essential Good Nutrition for Cancer Patients.
Stage 4 Lung Cancer - What Is It?
Stage 4 Lung Cancer - What Is It?
Wigs Help Patients Handle the Challenges of Treatment
Wigs Help Patients Handle the Challenges of Treatment
University Of Chicago Scientists Provide New Evidence For Cellular Cause Of Sids
University Of Chicago Scientists Provide New Evidence For Cellular Cause Of Sids
Oncotype DX as a Decision Tool in Early Breast Cancer
Oncotype DX as a Decision Tool in Early Breast Cancer
Practice of Medicine: Anxiety Up, Morale Down
Practice of Medicine: Anxiety Up, Morale Down
Surviving Breast Cancer - A Husband' s View
Surviving Breast Cancer - A Husband' s View
Breast Cancer Prevention Tips
Breast Cancer Prevention Tips
Journal Article: Adjuvant Chemotherapy for Stage 2 Colon Cancer
Journal Article: Adjuvant Chemotherapy for Stage 2 Colon Cancer
The D'Amico Classification System for Prostate Cancer
The D'Amico Classification System for Prostate Cancer
The Common Signs and Symptoms of Pancreatic Cancer
The Common Signs and Symptoms of Pancreatic Cancer

Leave Your Reply

*